MF

Nippon India Nifty Pharma ETF

IndexETFs - IndexBenchmark: NIFTY PHARMA - TRI
NAV · 15 Sep 2026₹26.93-1.30%
AUM₹1.8k Cr
Expense Ratio0.24%
5Y CAGR+13.11%
Exit Load
Min SIP
Launched2021

Investment Objective

The investment objective of the scheme is to provide investment returns closely corresponding to the total returns of the securities as represented by the NIFTY Pharma Index before expenses, subject to tracking errors. However, there can be no assurance or guarantee that the investment objective of the Scheme will be achieved.

Fund Mandate

MMI including Tri-Party Repo on G-Sec or T-Bills, cash & cash equivalents or Liquid Schemes0%–5%
Securities constituting NIFTY Pharma Index95%–100%
Asset Allocation
Domestic Equity99.9%
Cash & Equivalents0.1%
Fund Managers
JT
Jitendra Tolani
Fund Manager
Key Information
0.24%
₹1,000
Nil
Inception06 Jul 2021
AMC
Top Holdings
1Sun Pharmaceutical Industries LimitedPharmaceuticals & Biotechnology20.75%
2Divi's Laboratories LimitedPharmaceuticals & Biotechnology11.88%
3Cipla LimitedPharmaceuticals & Biotechnology7.83%
4Laurus Labs LimitedPharmaceuticals & Biotechnology7.36%
5Torrent Pharmaceuticals LimitedPharmaceuticals & Biotechnology7.34%
6Dr. Reddy's Laboratories LimitedPharmaceuticals & Biotechnology6.95%
7Lupin LimitedPharmaceuticals & Biotechnology5.25%
8Aurobindo Pharma LimitedPharmaceuticals & Biotechnology4.69%
9Glenmark Pharmaceuticals LimitedPharmaceuticals & Biotechnology3.69%
10Alkem Laboratories LimitedPharmaceuticals & Biotechnology3.08%
Sector Allocation
Pharmaceuticals & Biotechnology99.9%
Trailing Returns
PeriodReturnsCategory avg
1 Day-1.30%
1 Week-2.58%
1 Month-0.99%
3 Months+8.31%
6 Months+14.96%
9 Months+15.72%
1 Year+18.39%+6.59%
2 Years+6.09%
3 Years+19.36%+13.16%
4 Years+20.81%
5 Years+13.11%+12.23%
+12.79%

Category avg is the average return of every scheme in this fund's SEBI class (ETFs - Index) over the same period. Returns up to 1 year are absolute; returns beyond 1 year are annualised (CAGR). This is Accord's own stated convention for equity-oriented schemes.

Risk Metrics
14.75%

A measure of how much a fund's returns swing up and down over time. Higher means a bumpier ride — more volatility — even if the average return ends up the same as a steadier fund.

1.00

How sensitive a fund is to overall market moves. A beta of 1 means it roughly moves in line with the market; below 1 means smaller swings than the market; above 1 means bigger swings in both directions.

1.07

How much extra return a fund earned for every unit of risk (volatility) it took on, compared to a safe, risk-free investment. Higher means better risk-adjusted performance — not just higher returns, but smarter ones.

-0.19%

The extra return a fund generated above what its benchmark index would predict, given the risk it took. Positive alpha suggests the fund manager added genuine value beyond just tracking the market.

2.44

Similar to the Sharpe Ratio, but only counts downside volatility (the bad kind) rather than penalizing a fund for volatile-but-positive swings. Higher means better returns per unit of "harmful" risk.

-9.63%

The single worst peak-to-trough fall a fund has experienced over a given period — the deepest "how much would I have lost if I'd bought at the top and sold at the bottom" scenario.

Fees
0.24%
Nil
₹1,000
Capital Gains Tax, general rules

This is an equity-oriented fund. Under rules effective since Budget 2024 (23 July 2024):

Short-Term Capital Gains (held ≤ 12 months): taxed at a flat 20%.

Long-Term Capital Gains (held > 12 months): taxed at 12.5% on gains above ₹1.25 lakh in a financial year, with no indexation benefit.

General information only, not tax advice, actual liability depends on your overall income and applicable law at the time of redemption. Consult a tax advisor for your specific situation.

Frequently Asked QuestionsGeneral mutual-fund FAQs, not specific to this scheme